AMPHASTAR PHARMACEUTICALS INC (AMPH)

User Guide    Video Tutorial
Small-Cap Growth Investor Strategy Explanation Video

symbol lookup

Follow AMPH via My Validea and receive an email alert whenever any of our strategies changes its rating.

Get Started
Score: 83/100
Analysis based upon 2/29/2024 closing price.
Amphastar Pharmaceuticals, Inc. is a bio-pharmaceutical company. The Company is focused on developing, manufacturing, marketing and selling generic and injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (API) products. It operates through two segments: finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Primatene Mist is an epinephrine inhalation product, which is indicated for the temporary relief of mild symptoms of intermittent asthma. Its portfolio also includes BAQSIMI (BAK-see-mee), which is used to treat very low blood sugar in people with diabetes ages 4 years and above.

Report Card - Small-Cap Growth Investor

Guru Criteria: Motley Fool  
PROFIT MARGIN:PASS
RELATIVE STRENGTH:FAIL
COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR:PASS
INSIDER HOLDINGS:PASS
CASH FLOW FROM OPERATIONS:PASS
PROFIT MARGIN CONSISTENCY:PASS
R&D AS A PERCENTAGE OF SALES:PASS
CASH AND CASH EQUIVALENTS:PASS
INVENTORY TO SALES:PASS
ACCOUNTS RECEIVABLE TO SALES:PASS
LONG TERM DEBT/EQUITY RATIO:FAIL
"THE FOOL RATIO" (P/E TO GROWTH):PASS
AVERAGE SHARES OUTSTANDING:PASS
SALES:FAIL
DAILY DOLLAR VOLUME:PASS
PRICE:PASS
INCOME TAX PERCENTAGE:PASS

Detailed Analysis

Get a full analysis of AMPH using this and 11 other strategies of investment legends.

Start Your Free Trial
Performance Disclaimer: Returns presented on Validea.com are model returns and do not represent actual trading. As a result, they do not incorporate any commissions or other trading costs or fees. Model portfolios with inception dates on or after 12/30/2005 include a combination of back tested and live model returns. The back-tested performance results shown are hypothetical and are not the result of real-time management of actual accounts. The back-testing of performance differs from actual account performance because the investment strategy may be adjusted at any time, for any reason and can continue to be changed until desired or better performance results are achieved. Back-tested returns are presented to provide general information regarding how the underlying strategy behind the portfolio performed in our historical testing. A back-tested strategy has the benefit of hindsight and the results do not reflect the impact that material economic or market factors may have had on advisor's decision-making if actual client assets were being managed using this approach. The model portfolios offered on Validea are concentrated and as a result they will exhibit high levels of volatility and their performance can be substantially impacted by the performance of individual positions.

Optimal portfolios presented on Validea.com represent the rebalancing period that has led to the best historical performance for each of our equity models. Each optimal portfolio was determined after the fact with performance information that was not available at portfolio inception. As a result, an investor could not have invested in the optimal portfolio since its inception. Optimal portfolios are presented to allow investors to quickly determine the portfolio size and rebalancing period that has performed best for each of our models in our historical testing.

Both the model portfolio and benchmark returns presented for all equity portfolios on Validea.com are not inclusive of dividends. Returns for our ETF portfolios and trend following system, and the benchmarks they are compared to, are inclusive of dividends. The S&P 500 is presented as a benchmark because it is the most widely followed benchmark of the overall US market and is most often used by investors for return comparison purposes. As with any investment strategy, there is potential for profit as well as the possibility of loss and investors may incur a loss despite a past history of gains. Past performance does not guarantee future results. Results will vary with economic and market conditions.

Validea.com is a research provider that is owned and operated by The Reese Group, LLC. Validea.com offers model portfolios, screening and stock analysis that is not customized to any individual. No information on Validea.com should be construed as investment advice. Validea Capital Management is a separate investment advisory firm registered with the state of Connecticut. Validea Capital offers investment management services directly to clients and is a separate entity from The Reese Group, LLC. The Reese Group and Validea Capital are affiliated entities and share partial common ownership.